Fulcrum Therapeutics Stock Probability of Future Stock Price Finishing Over 3.72
| FULC Stock | USD 3.95 0.40 11.27% |
Fulcrum |
Fulcrum Therapeutics Target Price Odds to finish over 3.72
The tendency of Fulcrum Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay above $ 3.72 in 90 days |
| 3.95 | 90 days | 3.72 | about 61.25 |
Based on a normal probability distribution, the odds of Fulcrum Therapeutics to stay above $ 3.72 in 90 days from now is about 61.25 (This Fulcrum Therapeutics probability density function shows the probability of Fulcrum Stock to fall within a particular range of prices over 90 days) . Probability of Fulcrum Therapeutics price to stay between $ 3.72 and its current price of $3.95 at the end of the 90-day period is nearly 4.56 .
Given the investment horizon of 90 days Fulcrum Therapeutics has a beta of 0.85. This usually indicates Fulcrum Therapeutics market returns are highly-sensitive to returns on the market. As the market goes up or down, Fulcrum Therapeutics is expected to follow. Additionally Fulcrum Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Fulcrum Therapeutics Price Density |
| Price |
Predictive Modules for Fulcrum Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Fulcrum Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Fulcrum Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Fulcrum Therapeutics is not an exception. The market had few large corrections towards the Fulcrum Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Fulcrum Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Fulcrum Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.73 | |
β | Beta against Dow Jones | 0.85 | |
σ | Overall volatility | 1.96 | |
Ir | Information ratio | -0.08 |
Fulcrum Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Fulcrum Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Fulcrum Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Fulcrum Therapeutics generated a negative expected return over the last 90 days | |
| Fulcrum Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 2.81 M. Net Loss for the year was (97.33 M) with loss before overhead, payroll, taxes, and interest of (70.44 M). | |
| Fulcrum Therapeutics currently holds about 221.79 M in cash with (90.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 90.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Fulcrum Therapeutics stock hits 52-week low at 2.87 - Investing.com |
Fulcrum Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Fulcrum Stock often depends not only on the future outlook of the current and potential Fulcrum Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Fulcrum Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 61.3 M | |
| Cash And Short Term Investments | 236.2 M |
Fulcrum Therapeutics Technical Analysis
Fulcrum Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Fulcrum Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Fulcrum Therapeutics. In general, you should focus on analyzing Fulcrum Stock price patterns and their correlations with different microeconomic environments and drivers.
Fulcrum Therapeutics Predictive Forecast Models
Fulcrum Therapeutics' time-series forecasting models is one of many Fulcrum Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Fulcrum Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Fulcrum Therapeutics
Checking the ongoing alerts about Fulcrum Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Fulcrum Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Fulcrum Therapeutics generated a negative expected return over the last 90 days | |
| Fulcrum Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 2.81 M. Net Loss for the year was (97.33 M) with loss before overhead, payroll, taxes, and interest of (70.44 M). | |
| Fulcrum Therapeutics currently holds about 221.79 M in cash with (90.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 90.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Fulcrum Therapeutics stock hits 52-week low at 2.87 - Investing.com |
Check out Fulcrum Therapeutics Backtesting, Fulcrum Therapeutics Valuation, Fulcrum Therapeutics Correlation, Fulcrum Therapeutics Hype Analysis, Fulcrum Therapeutics Volatility, Fulcrum Therapeutics History as well as Fulcrum Therapeutics Performance. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.29) | Revenue Per Share 1.317 | Quarterly Revenue Growth 89.909 | Return On Assets (0.07) | Return On Equity (0.07) |
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.